Posts Tagged: pharmaceutical patent law


Federal Circuit Upholds Patent Term Extension for Novartis Drug

The United States Court of Appeals for the Federal Circuit recently affirmed a district court decision finding the '229 patent valid, unexpired, enforceable, and infringed, and granting …

Merck subsidiary Idenix wins $2.54B in HCV treatment suit against Gilead in largest U.S. patent infringement verdict ever

On Thursday, December 15th, a subsidiary of Kenilworth, NJ-based pharmaceutical developer Merck & Co. (NYSE:MRK) was awarded $2.54 in royalty damages in a case involving one of the …
By Steve Brachmann
4 years ago 1

UN Access to Medicine Recommendations Will Increase Human Suffering

The pending report of the UN Secretary General's High Level Panel on Access to Medicines not only attacks the patent system as predicted, but proposes giving the …
By Joseph Allen
5 years ago 7

Legal Threats to Strong Returns on Pharmaceutical Patents Grow, Threatening Innovation

Pharmaceuticals is the industry sector where a strong patent system, promising substantial returns to successful innovation, is of paramount importance. Regrettably, the weakening of pharmaceutical patent rights …
By Alden Abbott
5 years ago 12

FTC Report on Drug Patent Settlements Shows Substantial Decrease in Pay-for-Delay Deals

The number of these potentially anticompetitive deals has fallen significantly following the Supreme Court’s landmark antitrust decision in FTC v. Actavis in 2013. The total number of …

India, Pharmacy to the Developing World, Must Honor IP Rights

Claiming to be the ''Pharmacy to the Developing World'', India argues that their lax intellectual property rights regime is critical to their ability to provide low-cost, quality …

When Patents Aren’t Enough: The Case for Data Exclusivity for Biologic Medicines

Although complementary, patents and data exclusivity protection incentivize innovation in different ways and serve distinct purposes. Patents provide protection for innovations that meet the standards of patentability …

The Case for Incremental Innovation: The Importance of Protecting Follow-on Pharmaceutical Discoveries

The value of such innovation is best measured through the improved health outcomes for patients. In this context, a few examples from the developing world are even …

Why Actavis Is Not Limited to Cash: Professors Brief in Lamictal

First, the Actavis decision is not limited to cash. The case itself involved not cash payments, but brand overpayments for generic services. In addition, the Supreme Court’…
By Michael Carrier
7 years ago 0

The Future of Global Health Depends on Strong IPRs

At first blush Dr. David Taylor’s claim that “continuing progress in the pharmaceutical and other health sciences will eliminate disease related mortality and disability in people …

PLI Summer 2010 Schedule Highlighted With All New Courses

Summer is almost over, but the Practising Law Institute still has some great Intellectual Property courses that all come with CLE credits. So whether you are looking …
By Gene Quinn
11 years ago 0